A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

Mark A. Chambers; D. Craig Wright; Joan Brisker; Ann Williams; Graham Hatch; Dolores Gavier-Widén; Graham Hall; Philip D. Marsh; R. Glyn Hewinson

doi:10.1016/j.vaccine.2003.05.002

A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

Mark A. Chambers^*
, D. Craig Wright
, Joan Brisker
, Ann Williams
, Graham Hatch
, Dolores Gavier-Widén
, Graham Hall
, Philip D. Marsh
, R. Glyn Hewinson

^*Corresponding author for this work

Bovine TB, diseases and control

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Abstract

The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes™) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown

Original language	English
Pages (from-to)	1063-1071
Number of pages	9
Journal	Vaccine
Volume	22
Issue number	8
Early online date	14 Oct 2003
DOIs	https://doi.org/10.1016/j.vaccine.2003.05.002
Publication status	Published - 25 Feb 2004

Keywords

Liposome
M. bovis
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2003.05.002

Permanent link

Persistent link

Cite this

@article{fa4744d0a8f141ae99f135eaad47c01c,

title = "A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome{\texttrademark}) protects guinea pigs from lethal tuberculosis",

abstract = "The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes{\texttrademark}) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown",

keywords = "Liposome, M. bovis, Vaccine",

author = "Chambers, \{Mark A.\} and Wright, \{D. Craig\} and Joan Brisker and Ann Williams and Graham Hatch and Dolores Gavier-Wid{\'e}n and Graham Hall and Marsh, \{Philip D.\} and Hewinson, \{R. Glyn\}",

year = "2004",

month = feb,

day = "25",

doi = "10.1016/j.vaccine.2003.05.002",

language = "English",

volume = "22",

pages = "1063--1071",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

AU - Chambers, Mark A.

AU - Wright, D. Craig

AU - Brisker, Joan

AU - Williams, Ann

AU - Hatch, Graham

AU - Gavier-Widén, Dolores

AU - Hall, Graham

AU - Marsh, Philip D.

AU - Hewinson, R. Glyn

PY - 2004/2/25

Y1 - 2004/2/25

N2 - The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes™) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown

AB - The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes™) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown

KW - Liposome

KW - M. bovis

KW - Vaccine

UR - https://www.scopus.com/pages/publications/1242270634

U2 - 10.1016/j.vaccine.2003.05.002

DO - 10.1016/j.vaccine.2003.05.002

M3 - Article

C2 - 15161084

AN - SCOPUS:1242270634

SN - 0264-410X

VL - 22

SP - 1063

EP - 1071

JO - Vaccine

JF - Vaccine

IS - 8

ER -

A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

Abstract

Keywords

UN SDGs

Access to Document

Permanent link

Other files and links

Fingerprint

Cite this